Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Breast Cancer Clinical Trial

Official title:

PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMENT OF ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00721409
• Other study ID #: A5481003
• Secondary ID: 2008-002392-27
• Status: Completed
• Phase: Phase 2
• Start date: September 15, 2008
• Est. completion date: December 20, 2017

Study information

• Verified date: October 2019
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 177
• Est. completion date: December 20, 2017
• Est. primary completion date: November 29, 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inoperable estrogen receptor positive and HER2 negative breast cancer.

• Postmenopausal status.

• Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2
• CCND1 amplification and/or loss of p16 as determined by the central laboratory.

• Acceptable bone marrow, liver and kidney function.

Exclusion Criteria:

• Prior or concomitant treatment for advanced breast cancer.

• Other major cancer in the past 3 years.

• Important cardiovascular events in the past 6 months.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• PD 0332991
125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
• letrozole
2.5 mg/d tablets orally on a continuous regimen
• letrozole
2.5 mg/d tablets orally on a continuous regimen

Locations

Country	Name	City	State
Canada	CSSS Champlain-Charles-Le Moyne Local HS-0054	Greenfield Park	Quebec
Canada	BC Cancer Agency - Vancouver Centre	Vancouver	British Columbia
France	Centre Paul Papin, CRLCC	ANGERS Cedex 9
France	CHD Vendee	La Roche Sur Yon
Germany	Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim	Berlin
Germany	Gemeinschaftspraxis Haematologie-Onkologie	Dresden
Germany	Martin-Luther-Universitaet Halle-Wittenberg	Halle/Saale
Germany	Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg	Halle/Saale
Germany	Nationales Centrum fuer Tumorerkrankungen	Heidelberg
Germany	Frauenaerzte Pruener Gang Abts & Partner	Kiel
Germany	Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz	Mainz
Germany	Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen	Muenchen
Germany	Frauenklinik vom Roten Kreuz	Muenchen
Germany	Onkolog. Gemeinschaftspraxis	Muenchen
Germany	Mutterhaus der Borromaeerinnen, Innere Medizin I	Trier
Hungary	Fovarosi Onkormanyzat Uzsoki Utcai Korhaz	Budapest
Hungary	Orszagos Onkologiai Intezet, Kemoterapia B	Budapest
Hungary	Szent Margit Korhaz, Onkologia	Budapest
Hungary	Petz Aladar Megyei Oktato Korhaz, Onkoradiologia	Gyor
Hungary	Borsod-Abauj-Zemplen Megyei Korhaz és Egyetemi Oktato Korhaz, Onkologia	Miskolc
Hungary	Szabolcs-Szatmar-Bereg Megyei Korhazak es	Nyiregyhaza
Hungary	Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly	Szombathely
Ireland	Bon Secours Hospital	Cork
Ireland	Mater Misericordiae University Hospital	Dublin
Ireland	Mater Private Hospital	Dublin
Ireland	St. Vincent's University Hospital	Dublin
Ireland	St. James's Hospital	Dublin 8
Italy	M.O. di Oncologia - Azienda USL di Rimini - Ospedale "Cervesi"	Cattolica
Italy	Ospedale Civile di Faenza Centro Oncologico	Faenza, RA
Italy	Unita' Operativa di Oncologia, Ospedale Civile di Lugo	Lugo, RA
Italy	Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST	Meldola	FC
Italy	Ospedale Civile di Ravenna	Ravenna
Italy	Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi	Rimini
Italy	Ospedale Villa San Pietro	Roma
Korea, Republic of	National Cancer Center, Center for Breast Cancer	Goyang-si	Gyeonggi-do
Korea, Republic of	Samsung Medical Center	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul
Russian Federation	Federal State Budgetary Scientific Institution	Moscow
Russian Federation	Pyatigorsk Oncology Center	Pyatigorsk
Russian Federation	State Budgetary Healthcare Institution "Samara Regional Clinical Oncology Dispensary"	Samara
Russian Federation	Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic	Ufa
South Africa	Department of Oncotherapy, National Hospital	Bloemfontein
South Africa	Eastleigh Breast Care Centre	Pretoria
Spain	Hospital General Universitario Vall D'Hebron	Barcelona
Spain	Ico-Hospitalet	Hospitalet de Llobregat	Barcelona
Spain	Centro Oncologico de Galicia	La Coruña
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario Virgen Del Rocio	Sevilla
Ukraine	Department of Oncology and Medical Radiology, SI "DMA of MOH, Ukraine, "MI "Dnipropetrovsk City	Dnipropetrovsk
Ukraine	Municipal clinical treatment-and-propyilactic institution "Donetsk regional oncology center',	Donetsk
Ukraine	Municipal Treatment-and-Prophylactic Institution 'Donetsk City Oncological Dispensary' Radiology dep	Donetsk
Ukraine	Kyiv City Clinical Oncologic Center	Kyiv
Ukraine	Lviv State Oncologic Regional Treatment and Diagnostic Centre	Lviv
United States	Central Hematology Oncology Medical group Inc.	Alhambra	California
United States	UCLA Hematology/Oncology - Alhambra	Alhambra	California
United States	Virginia Cancer Specialists, PC	Arlington	Virginia
United States	CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center	Bakersfield	California
United States	Illinois Cancer Specialists	Chicago	Illinois
United States	Resurrection Medical Group	Chicago	Illinois
United States	North Shore Oncology-Hematology Associates	Crystal Lake	Illinois
United States	Texas Oncology-Baylor Charles A. Sammons Cancer Center	Dallas	Texas
United States	Texas Oncology-Dallas Presbyterian Hospital	Dallas	Texas
United States	Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care	Duluth	Georgia
United States	Virginia Cancer Specialists, PC	Fairfax	Virginia
United States	Investigational Products Center (IPC)	Fort Worth	Texas
United States	US Oncology Research and Clinical Pharmacy	Fort Worth	Texas
United States	St. Joseph Heritage Healthcare	Fullerton	California
United States	Virginia Cancer Specialists, PC	Gainesville	Virginia
United States	Comprehensive Cancer Centers of Nevada	Henderson	Nevada
United States	Comprehensive Cancer Centers of Nevada	Henderson	Nevada
United States	Regulatory Office: Comprehensive Cancer Centers of Nevada	Henderson	Nevada
United States	North Shore Hematology Oncology	Highland Park	Illinois
United States	Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada
United States	Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada
United States	Comprehensive Cancer Centers of Nevada	Las Vegas	Nevada
United States	Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care	Lawrenceville	Georgia
United States	Virginia Cancer Specialists, PC	Leesburg	Virginia
United States	North Shore Oncology-Hematology Associates	Libertyville	Illinois
United States	Drug Management Only	Los Angeles	California
United States	Drug Management Only: UCLA West Medical Pharmacy	Los Angeles	California
United States	Regulatory Managment	Los Angeles	California
United States	Ronald Reagan UCLA Medical Center	Los Angeles	California
United States	Ronald Reagan UCLA Medical Center	Los Angeles	California
United States	TORI -US Central Administration	Los Angeles	California
United States	TORI -US Central Administration (Regulatory Management)	Los Angeles	California
United States	TORI Central Administration (Regulatory Management)	Los Angeles	California
United States	TORI Central Administration (Regulatory Managment Only)	Los Angeles	California
United States	TRIO-US Central Administration	Los Angeles	California
United States	UCLA Hematology/Oncology	Los Angeles	California
United States	UCLA West Medical Pharmacy	Los Angeles	California
United States	UCLA West Medical Pharmacy	Los Angeles	California
United States	UCLA West Medical Pharmacy (Drug Management Only)	Los Angeles	California
United States	UCLA, Hematology/Oncology	Los Angeles	California
United States	Westwood Bowyer Clinic, Peter Morton Medical Building	Los Angeles	California
United States	Central Hematology Oncology Medical Group, Inc	Pasadena	California
United States	Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates	Redondo Beach	California
United States	Sansum Santa Barbara Medical Foundation Clinic	Santa Barbara	California
United States	Central Coast Medical Oncology Corporation	Santa Maria	California
United States	Santa Monica-UCLA Medical Center and Orthopaedic Hospital	Santa Monica	California
United States	UCLA Hematology Oncology-Santa Monica	Santa Monica	California
United States	North Shore Hematology Oncology	Skokie	Illinois
United States	Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care	Snellville	Georgia
United States	UCLA Hematology/Oncology - Santa Clarita	Valencia	California
United States	Virginia Cancer Specialists, PC	Woodbridge	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Canada,  France,  Germany,  Hungary,  Ireland,  Italy,  Korea, Republic of,  Russian Federation,  South Africa,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1	An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.	Maximum treatment duration (approximately 55 months)
Primary	Number of Participants With Treatment-Related Adverse Events at Phase 1	An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.	Maximum treatment duration (approximately 55 months)
Primary	Number of Participants With Dose Limiting Toxicities at Phase 1	Dose limiting toxicity was defined as any of the following TEAEs occurring during the second cycle of treatment and possibly attributable to the combination of letrozole plus Palbociclib: 1. Grade 4 hematologic toxicity (including platelets <25,000/µL, ANC <500/µL). 2. Grade 3 neutropenia associated with a documented infection or fever =38.5°C. 3. Grade =3 non-hematologic toxicities, except those that have not been maximally treated (eg, nausea, vomiting, diarrhea, hypertension). 4. Delay by =1 week in receiving the next scheduled dose of either study treatment due to persisting treatment-related toxicities (platelet count <50,000/µL; ANC <1,000/µL; nonhematologic toxicities of Grade =3 severity). 5. Inability to deliver at least 80% of the planned Palbociclib or letrozole doses during Cycle 2 due to toxicity possibly attributable to the study treatment.	Cycle 2 (4 weeks)
Primary	Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment	PFS was defined as the time from randomization (or the first dose of study treatment for non-randomized studies) to the first documentation of objective tumor progression or to death due to any cause, whichever occurred first. PFS calculated as (Weeks or Months) = (first event date minus randomization or the first dose date plus 1) divided by 7 (or 30.44 if in months). PFS is usually characterized by the median, 25% percentile,75% percentile and their 95% Confidence Intervals (CIs).	From randomization date to date of first documentation of progression or death (assessed up to 41 months)
Secondary	Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1	Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as =30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.	From Baseline up to end of study (assessed up to 55 months)
Secondary	Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1	CBR is defined as a confirmed CR, confirmed PR, or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persisted on repeat imaging >= 4 weeks after initial response.	From Baseline up to end of study (assessed up to 55 months)
Secondary	Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1	On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.	Cycle 1 Day 14, and Cycle 2 Day 14
Secondary	Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1	On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.	Cycle 1 Day 14, and Cycle 2 Day 14
Secondary	Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1	On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.	Cycle 1 Day 14, and Cycle 2 Day 14
Secondary	Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1	On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.	Cycle 1 Day 14, and Cycle 2 Day 14
Secondary	Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1	On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.	Cycle 1 Day 14, and Cycle 2 Day 14
Secondary	Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1	On Cycle 1 Day 14, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, 24, 48, 96 and 120 hours after Palbociclib dosing. On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing.	Cycle 1 Day 14, and Cycle 2 Day 14
Secondary	Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1	On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.	Cycle 2 Day 14, Cycle 2 Day 28
Secondary	Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1	On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.	Cycle 2 Day 14, and Cycle 2 Day 28
Secondary	Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1	On Cycle 2 Day 14, plasma pharmacokinetic samples for Palbociclib and letrozole were collected prior to and 1, 2, 4, 8, 12 and 24 hours after Palbociclib and letrozole dosing. On Cycle 2 Day 28, plasma pharmacokinetic samples were collected prior to and 1, 2, 4, 8, 12, and 24 hours after letrozole dosing.	Cycle 2 Day 14, and Cycle 2 Day 28
Secondary	Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1	Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Participants with maximum increase from baseline of 30 to less than (<) 60 msec(borderline) and greater than or equal to (>=) 60 msec (prolonged) were summarized.	Cycle 1 Day 1 prior to dosing, Cycle 1 Day 14 (2, 4 [prior to meal], 8, 24, 48, and 96 hours after dosing of Palbociclib), Cycle 2 Day 1 and Day 14 (prior to and 4 hours after dosing of letrozole)
Secondary	Overall Survival (OS) at Phase 2	Time in weeks or months from randomization to date of death due to any cause. OS was calculated as (the death date or last known alive date (if death date unavailable) minus the date of randomization plus 1) divided by 7 or 30.44 if in months.	From randomization until death (assessed up to 86 months)
Secondary	Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment	Percentage of participants with objective response based assessment of confirmed CR or confirmed PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as =30% decrease in sum of the longest diameters (LD) of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions.	From randomization up to the end of treatment (approximately 41 months)
Secondary	Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment	Percentage of participants with objective response based assessment of confirmed CR or PR according to RECIST. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. Per RECIST v1.0: CR defined as disappearance of all target lesions and non-target lesions. PR defined as =30% decrease in sum of the LD of the target lesions taking as a reference the baseline sum LD according to RECIST associated to non-progressive disease response for non target lesions. Measurable disease referred to the lesions that was accurately measured in at least 1 dimension (longest diameter to be recorded) as =20 mm with conventional techniques or as =10-16 mm with spiral computer tomography scan (depending on reconstruction interval). Clinical lesions were only be considered measurable when they were superficial (eg, skin nodules, palpable lymph nodes).	From randomization up to the end of treatment (approximately 41 months)
Secondary	Duration of Response at Phase 2 - Investigator Assessment	Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).	From randomization up to the end of treatment (approximately 41 months)
Secondary	Number of Participants With CBR at Phase 2 - Investigator Assessment	CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST.	From randomization up to the end of treatment (approximately 41 months)
Secondary	Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment	Time in weeks, (months or years) from randomization or (start of study treatment for non-randomized studies) to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of randomization [or first dose of study medication for non-randomized studies] plus 1) divided by 7 or 30.44 if in months. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD] per RECIST).	From randomization up to the end of treatment (approximately 41 months)
Secondary	Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2	The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").	Baseline, End of treatment (approximately 41 months)
Secondary	Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2	The mBPI-sf is a validated and reliable self-report questionnaire which consists of 13 questions that assess the severity and impact of pain on daily function. The 13 items of the questionnaire make up two scales and two single items. The scales include the 4-item Pain Severity Scale (worst pain, least pain, average pain, and pain right now) and the 7-item Pain Interference Scale (general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life). Each item of the pain severity and pain interference scales are based on a 11-point numeric rating scale from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").	Baseline, End of treatment (approximately 41 months)
Secondary	Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1	Tissue samples were used for retrospective biomarker analyses. For Phase 2 Part 2, the tissue samples were sent to a central laboratory for the assessment of participant selection biomarkers. For Phase 2 Part 1, the assessment of the biomarkers (CCND1 amplification and/or loss of p16) were performed retrospectively from the available samples.	Screening visit (= 28 Days prior to dosing)
Secondary	Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67	Frequency of tumor tissue biomarker Ki67 was evaluated in across treatment groups.	Screening visit (= 28 Days prior to dosing)
Secondary	Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1	Presence or absence of tumor RB and CyclinD1 were evaluated. The following definitions of expression applied in the below table: Positive: any expression >0 and Negative: any expression=0.	Screening visit (= 28 Days prior to dosing)
Secondary	Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2	Gene copy number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) were evaluated. This analysis was done for Phase 2 combined group.	Screening visit (= 28 Days prior to dosing)
Secondary	Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2	One 2-mL blood specimen was collected for the analysis of germline polymorphism in CYP19A1 and CCND1 genes. A single nucleotide polymorphism (SNP) rs4646 as defined in the National Center for Biotechnology Information (NCBI) database in the aromatase gene (CYP19A1) was analyzed. A germline polymorphism G/A870 (rs9344) in the CCND1 gene was analyzed.	Screening visit (= 28 Days prior to dosing)
Secondary	Number of Participants With TEAEs (All Causalities) at Phase 2	AE:any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.AEs included both serious and non-serious AEs.SAE:AE resulting in any of following outcomes/deemed significant and jeopardized participants or required treatment to prevent other AE outcomes for any other reason:death;initial or prolonged inpatient hospitalization;life-threatening experience (immediate risk of dying);persistent or significant disability/incapacity;congenital anomaly.Treatment emergent AEs:events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or worsened relative to pre-treatment state.AEs were graded as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded using Medical Dictionary for Regulatory Activities (MedDRA). Participants with AE of grade 3 or 4 and grade 5 were reported as Grade 3:Severe, Grade 4:Life threatening, Grade 5:Death related to AE.	Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)
Secondary	Number of Participants With Treatment-Related Adverse Events at Phase 2	AE: any untoward medical occurrence in a participant who received study drug. AEs included both serious and non-serious adverse events. SAE: AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment emergent AEs: events occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Treatment related AEs: all AEs with causality related to treatment. Relatedness to drug was assessed by the investigator. AEs were graded according to the CTCAE version 3.0 and coded using the MedDRA. Number of participants with AE of grade 3 or 4 and with AE of grade 5 were reported as Grade 3: Severe, Grade 4: Life threatening, Grade 5: Death related to AE.	Baseline up to 28 days after last dose of study drug (for a maximum of 86 months)

External Links

•   To obtain contact information for a study center near you, click here.